Cubicin - (500 mg/vial; Powder, Intravenous)

Generic Name	Daptomycin	**Innovator**	CUBIST Pharma
Dosage	500 mg/vial; Powder, Intravenous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI)		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.